Cowen Expands Biotechnology Equity Research Team with Addition of Chris Shibutani, MD

NEW YORK--()--Cowen Group, Inc. (“Cowen”) (NASDAQ:COWN) today announced that Chris Shibutani, MD has joined Cowen and Company’s equity research department as a Managing Director to cover biotechnology stocks. Dr. Shibutani is based in Boston and reports to Robert Fagin, Cowen’s Director of Research.

“We are thrilled to welcome Dr. Shibutani to Cowen,” said Mr. Fagin. “His incredible scholarship and breadth and depth of investment experience make him a perfect fit with our world-class health care effort.”

Dr. Shibutani began his Wall Street career at Hambrecht & Quist (later JP Morgan), where he covered a variety of health care sectors, including medical devices, life science tools, biotechnology and major pharmaceuticals over a nearly 10-year period. He served as JP Morgan's global sector coordinator for major pharmaceuticals for three years. Dr. Shibutani also has eight years of buyside investing experience, having served in health care analyst and portfolio manager roles at UBS Global Asset Management and Pioneer Investment Management. He was also a consultant at Druganalyst Ltd.

Dr. Shibutani holds a BA, cum laude, in biology from Harvard University, an MD from Columbia College of Physicians and Surgeons, and an MBA from Columbia Business School. He was a medical intern in the Department of Internal Medicine at Columbia Presbyterian Medical Center, and was Resident and Clinical Fellow in Massachusetts General Hospital's Department of Anesthesiology and Critical Care. Dr. Shibutani was later on the Clinical Faculty of the Department of Anesthesiology and Critical Care at Memorial Sloan-Kettering Cancer Center.

About Cowen Group, Inc.

Cowen Group, Inc. is a diversified financial services firm and, together with its consolidated subsidiaries, provides alternative asset management, investment banking, research, and sales and trading services through its two business segments: Ramius and its affiliates make up the Company’s alternative investment segment, while Cowen and Company and its affiliates make up the Company’s broker-dealer segment. Ramius provides alternative asset management solutions to a global client base and manages a significant portion of Cowen’s proprietary capital. Cowen and Company and its affiliates offer industry focused investment banking for growth-oriented companies, domain knowledge-driven research, a sales and trading platform for institutional investors and a comprehensive suite of prime brokerage services. Founded in 1918, the firm is headquartered in New York and has offices worldwide.

Contacts

Sard Verbinnen & Co
Dan Gagnier / Carissa Felger, 212-687-8080

Release Summary

COWEN EXPANDS BIOTECHNOLOGY EQUITY RESEARCH TEAM WITH ADDITION OF CHRIS SHIBUTANI, MD

Contacts

Sard Verbinnen & Co
Dan Gagnier / Carissa Felger, 212-687-8080